Literature DB >> 9031578

Combined pharmacotherapy in children and adolescents in a residential treatment center.

D F Connor1, K R Ozbayrak, K A Kusiak, A B Caponi, R H Melloni.   

Abstract

OBJECTIVE: To investigate characteristics of children and adolescents with a history of combined pharmacotherapy (CPT) and compare them with a group with no history of CPT.
METHOD: Eighty-three consecutive admissions to a residential treatment center were divided into a CPT and a no-CPT group based on treatment history and compared by chart review. Prevalence of lifetime psychiatric medication use and CPT exposure were assessed. Demographic, diagnostic, treatment, behavioral, and medication variables were compared across the two groups.
RESULTS: Medication use was present in the treatment history for 89.2% and a history of CPT was found for 60.3% of subjects. Admission to current placement from inpatient psychiatry, lifetime number of psychiatric placements, lifetime number of psychiatric diagnoses, and nonseizure neuropsychiatric comorbidity were significantly associated with CPT. Aggression and neuroleptic use were also significantly associated with CPT. Admission psychiatric diagnostic comorbidity was not associated with CPT.
CONCLUSIONS: A high prevalence of psychiatric medication use and CPT was found in this population. Variables assessing illness severity, aggressive behavior, and nonseizure neuropsychiatric comorbidity may identify youths in psychiatric treatment settings with a high prevalence of past or current CPT exposure. Further research on the CPT of aggression is warranted.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9031578     DOI: 10.1097/00004583-199702000-00016

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  11 in total

1.  Trends in psychotropic polypharmacy among youths enrolled in Ohio Medicaid, 2002-2008.

Authors:  Cynthia A Fontanella; Lynn A Warner; Gary S Phillips; Jeffrey A Bridge; John V Campo
Journal:  Psychiatr Serv       Date:  2014-10-31       Impact factor: 3.084

2.  Forecasting length of stay in child residential treatment.

Authors:  David L Hussey; Shenyang Guo
Journal:  Child Psychiatry Hum Dev       Date:  2005

3.  Pharmacotherapy and postdischarge outcomes of child inpatients admitted for aggressive behavior.

Authors:  Joseph C Blader
Journal:  J Clin Psychopharmacol       Date:  2006-08       Impact factor: 3.153

Review 4.  Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Authors:  J S Markowitz; K S Patrick
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.

Authors:  Joseph C Blader; Nina R Schooler; Peter S Jensen; Steven R Pliszka; Vivian Kafantaris
Journal:  Am J Psychiatry       Date:  2009-11-02       Impact factor: 18.112

6.  Gender differences in reactive and proactive aggression.

Authors:  Daniel F Connor; Ronald J Steingard; Jennifer J Anderson; Richard H Melloni
Journal:  Child Psychiatry Hum Dev       Date:  2003

7.  Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.

Authors:  Hao-Jie Zhu; Jun-Sheng Wang; Jennifer L Donovan; Yan Jiang; Bryan B Gibson; C Lindsay DeVane; John S Markowitz
Journal:  Eur J Pharmacol       Date:  2007-10-05       Impact factor: 4.432

8.  An in vitro evaluation of guanfacine as a substrate for P-glycoprotein.

Authors:  Nancy K Gillis; Hao-Jie Zhu; John S Markowitz
Journal:  Neuropsychiatr Dis Treat       Date:  2011-08-26       Impact factor: 2.570

9.  Predictive factors for polypharmacy among child and adolescent psychiatry inpatients.

Authors:  Paul S S Russell; Christina George; Priya Mammen
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-09-22

Review 10.  Defining pediatric polypharmacy: A scoping review.

Authors:  Paul M Bakaki; Alexis Horace; Neal Dawson; Almut Winterstein; Jennifer Waldron; Jennifer Staley; Elia M Pestana Knight; Sharon B Meropol; Rujia Liu; Hannah Johnson; Negar Golchin; James A Feinstein; Shari D Bolen; Lawrence C Kleinman
Journal:  PLoS One       Date:  2018-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.